Alethia Biotherapeutics Inc.

Alethia Biotherapeutics Inc.

November 07, 2012 11:54 ET

Alethia Biotherapeutics Receives Notice of a Decision to Grant European Patent for its Siglec-15 Bone Antiresorptive

MONTREAL, QUÉBEC--(Marketwire - Nov. 7, 2012) - Alethia Biotherapeutics Inc., a privately held biotechnology company focusing on the development of therapeutic monoclonal antibodies announced today that the company has been granted its first Siglec-15 European patent entitled " Polynucleotides and Polypeptide Sequences Involved in the Process of Bone Remodeling" (Patent No. 1994155). This patent covers the use of anti-Siglec-15 antibodies, Siglec-15 protein and Siglec-15 cDNA or antisenses for modulating osteoclast differentiation and for treating or preventing bone diseases. This patent also covers methods for obtaining Siglec-15 inhibitors. Mr. Yves Cornellier, President & CEO of Alethia commented, "We are very pleased at receiving this notice of decision to grant a European patent for Siglec-15. This is an important milestone for Alethia as it confers a robust and broad intellectual property protection for our Siglec-15 development program".

Alethia has demonstrated that Siglec-15 is an important regulator of osteoclast differentiation and function. In several pathologies, bone remodeling is impaired due to increased osteoclastic activity which leads to decreased bone density and strength. Current antiresorptive therapies reduce osteoclast activity but most also impair bone formation. Alethia's bone antiresorptive program was purposefully designed to develop a new generation of therapies that decrease osteoclast activity while maintaining bone formation.

Dr. Mario Filion, Chief Scientific Officer of Alethia commented, "This patent illustrates the robustness of our discovery approach for innovative clinically-relevant therapeutic targets. Data from pre-clinical in vivo models of bone loss demonstrate that the results obtained with Siglec-15 antibodies are distinctive from those obtained with other anti-resorptive therapies. In particular, inhibition of Siglec-15 resulted in sustained antiresorptive activity coupled with maintenance of bone formation; a profile that, if translated in the clinic, would differentiate this product from currently marketed drugs".

About Alethia Biotherapeutics Inc.

Alethia is a privately held, Montreal-based biotechnology company created in 2002. Alethia develops monoclonal antibody therapeutics against novel clinically relevant targets identified using its patented STAR discovery technology. Alethia is well funded with top-tier investors committed to the success of the Company notably, Agechem Venture Fund, BDC Capital and GO Capital.

Contact Information